Summary
Global Markets Direct’s, ‘Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Inovio Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Inovio Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Inovio Pharmaceuticals, Inc.
- The report provides overview of Inovio Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Inovio Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Inovio Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Inovio Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Inovio Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Inovio Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Inovio Pharmaceuticals, Inc. Snapshot 7
Inovio Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Inovio Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Inovio Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Inovio Pharmaceuticals, Inc. - Pipeline Products Glance 17
Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Inovio Pharmaceuticals, Inc. - Drug Profiles 20
VGX-3100 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
INO-8000 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
FVH-1 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
influenza [strain A/H3N2] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
INO-1400 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
INO-3106 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
INO-3510 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
INO-4212 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INO-4500 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
INO-5150 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PENNVAX-B 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PENNVAX-G 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PENNVAX-GP 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VGX-3400X 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VRC-01 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
chikungunya vaccine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Clostridium difficile vaccine 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gene Therapy for Ebola Virus Infections 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
influenza [strain A/H7N9] vaccine 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
INO-5400 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MAV-12 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Monoclonal Antibodies to Inhibit Tyrosinase for Oncology and Immunology 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Monoclonal Antibody for Chikungunya 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
respiratory syncytial virus vaccine 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RSQ-15 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Vaccine for Cancer 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Vaccines for Neurological Disorders 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Inovio Pharmaceuticals, Inc. - Pipeline Analysis 51
Inovio Pharmaceuticals, Inc. - Pipeline Products by Target 51
Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 53
Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 54
Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 55
Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates 56
Inovio Pharmaceuticals, Inc. - Dormant Projects 66
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products 67
Discontinued Pipeline Product Profiles 67
mifepristone 67
VGX-410C 67
Inovio Pharmaceuticals, Inc. - Company Statement 68
Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73
List of Tables
Inovio Pharmaceuticals, Inc., Key Information 7
Inovio Pharmaceuticals, Inc., Key Facts 7
Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2016 9
Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 11
Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 12
Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 13
Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 15
Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Inovio Pharmaceuticals, Inc. - Phase II, 2016 17
Inovio Pharmaceuticals, Inc. - Phase I, 2016 18
Inovio Pharmaceuticals, Inc. - Preclinical, 2016 19
Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2016 52
Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 53
Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 54
Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 55
Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 56
Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 66
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 67
Inovio Pharmaceuticals, Inc., Subsidiaries 71
List of Figures
Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 9
Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 11
Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 12
Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 51
Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 53
Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 54
Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 55
